Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts

Documenti analoghi

• Clinical performance and effect of pre‐analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology
  di: Christopher M. Rank, et al.
  Pubblicazione: (2025)
• A protein panel including pTau217 outperforms pTau217 alone in identifying high tau load in amyloid positive individuals
  di: Guglielmo Di Molfetta, et al.
  Pubblicazione: (2025)
• Repeat Testing Reliability of Plasma pTau217 in Preclinical AD
  di: Robert A. Rissman, et al.
  Pubblicazione: (2024)
• Plasma pTau217 as a marker of both the current and future state of amyloid pathology in adults with DS
  di: Julie K. Wisch, et al.
  Pubblicazione: (2025)
• Comparing the diagnostic performance of plasma pTau181 and pTau217 for the identification of Alzheimer’s disease co‐pathology in Lewy Body Disease
  di: Alena Smith, et al.
  Pubblicazione: (2024)